reportlinker.com/p01080559/Pharmaceuticals-Global-Industry-Almanac-MarketLine.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical
Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Includes a five-year forecast of the industry
Americas accounts for 42.2% of the global pharmaceuticals market value.
Pfizer is the leading player in the global pharmaceuticals market, generating a 8.7% share of the market’s value.
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Table 1: Global pharmaceuticals market value: $ billion, 2007-11 37
Table 2: Global pharmaceuticals market geography segmentation: $ billion, 2011 38
Table 3: Global pharmaceuticals market share: % share, by value, 2011 39
Table 4: Global pharmaceuticals market value forecast: $ billion, 2011-16 40
Table 6: Asia-Pacific pharmaceuticals market geography segmentation: $ billion, 2011 51
Table 263: Pfizer Inc.: key facts 450
Table 264: Pfizer Inc.: key financials ($) 451
Table 265: Pfizer Inc.: key financial ratios 451
Table 266: GlaxoSmithKline Plc: key facts 453
Table 267: GlaxoSmithKline Plc: key financials ($) 454
Table 268: GlaxoSmithKline Plc: key financials () 455
Table 269: GlaxoSmithKline Plc: key financial ratios 455
Table 270: AstraZeneca PLC: key facts 457
Table 271: AstraZeneca PLC: key financials ($) 458
Table 272: AstraZeneca PLC: key financial ratios 459
Table 273: Merck & Co., Inc.: key facts 461
Table 274: Merck & Co., Inc.: key financials ($) 462
Table 275: Merck & Co., Inc.: key financial ratios 462
Table 276: Daiichi Sankyo Co., Ltd.: key facts 464
Table 277: Daiichi Sankyo Co., Ltd.: key financials ($) 465
Table 278: Daiichi Sankyo Co., Ltd.: key financials () 465
Table 279: Daiichi Sankyo Co., Ltd.: key financial ratios 465
Table 280: Astellas Pharma Inc.: key facts 467
Table 281: Astellas Pharma Inc.: key financials ($) 468
Table 282: Astellas Pharma Inc.: key financials () 468
Table 283: Astellas Pharma Inc.: key financial ratios 468
Table 284: Novartis AG: key facts 470
Table 285: Novartis AG: key financials ($) 471
Table 286: Novartis AG: key financial ratios 471
Table 287: Ach Laboratrios Farmacuticos S.A.: key facts 473
Table 288: Medley Indstria Farmacutica Ltd: key facts 474
Table 289: Sanofi: key facts 475
Table 290: Sanofi: key financials ($) 476
Table 291: Sanofi: key financials (€) 476
Table 292: Sanofi: key financial ratios 476
Table 293: EMS Sigma Pharma: key facts 478
Table 294: Johnson & Johnson: key facts 479
Table 295: Johnson & Johnson: key financials ($) 480
Table 296: Johnson & Johnson: key financial ratios 480
Table 297: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 482
Table 298: Orifarm A/S: key facts 483
Table 299: Gedeon Richter Plc: key facts 484
Table 300: Gedeon Richter Plc: key financials ($) 485
Table 301: Gedeon Richter Plc: key financials (HUF) 485
Table 302: Gedeon Richter Plc: key financial ratios 485
Table 303: EGIS Pharmaceuticals Plc: key facts 487
Table 304: EGIS Pharmaceuticals Plc: key financials ($) 488
Table 305: EGIS Pharmaceuticals Plc: key financials (HUF) 488
Table 306: EGIS Pharmaceuticals Plc: key financial ratios 488
Table 307: Dr. Reddy’s Laboratories Limited: key facts 490
Table 308: Dr. Reddy’s Laboratories Limited: key financials ($) 491
Table 309: Dr. Reddy’s Laboratories Limited: key financials (Rs.) 491
Table 310: Dr. Reddy’s Laboratories Limited: key financial ratios 491
Table 311: Cipla Limited: key facts 493
Table 312: Cipla Limited: key financials ($) 494
Table 313: Cipla Limited: key financials (Rs.) 494
Table 314: Cipla Limited: key financial ratios 494
Table 315: Ranbaxy Laboratories Limited: key facts 496
Table 316: Ranbaxy Laboratories Limited: key financials ($) 497
Table 317: Ranbaxy Laboratories Limited: key financials (Rs.) 497
Table 318: Ranbaxy Laboratories Limited: key financial ratios 497
Table 319: Lupin Limited: key facts 499
Table 320: Lupin Limited: key financials ($) 500
Table 321: Lupin Limited: key financials (Rs.) 500
Table 322: Lupin Limited: key financial ratios 501
Table 323: Chiesi Farmaceutici S.P.A.: key facts 503
Table 324: Menarini Group, The: key facts 505
Table 325: Takeda Pharmaceutical Company Limited: key facts 506
Table 326: Takeda Pharmaceutical Company Limited: key financials ($) 507
Table 327: Takeda Pharmaceutical Company Limited: key financials () 507
Table 328: Takeda Pharmaceutical Company Limited: key financial ratios 507
Table 329: Mitsubishi Tanabe Pharma Corporation: key facts 509
Table 330: Mitsubishi Tanabe Pharma Corporation: key financials ($) 510
Table 331: Mitsubishi Tanabe Pharma Corporation: key financials () 510
Table 332: Mitsubishi Tanabe Pharma Corporation: key financial ratios 510
Table 333: Eli Lilly and Company: key facts 512
Table 334: Eli Lilly and Company: key financials ($) 513
Table 335: Eli Lilly and Company: key financial ratios 513
Table 336: Polpharma SA: key facts 515
Table 337: Pharmstandard OJSC: key facts 516
Table 338: Pharmstandard OJSC: key financials ($) 516
Table 339: Pharmstandard OJSC: key financials (RUB) 517
Table 340: Pharmstandard OJSC: key financial ratios 517
Table 341: Bayer AG: key facts 519
Table 342: Bayer AG: key financials ($) 520
Table 343: Bayer AG: key financials (€) 520
Table 344: Bayer AG: key financial ratios 521
Table 345: Aspen Pharmacare Holdings Ltd: key facts 523
Table 346: Aspen Pharmacare Holdings Ltd: key financials ($) 524
Table 347: Aspen Pharmacare Holdings Ltd: key financials (ZAR) 524
Table 348: Aspen Pharmacare Holdings Ltd: key financial ratios 524
Table 349: Daewoong Pharmaceutical Co., Ltd.: key facts 526
Table 350: Daewoong Pharmaceutical Co., Ltd.: key financials ($) 527
Table 351: Daewoong Pharmaceutical Co., Ltd.: key financials (KRW) 527
Table 352: Daewoong Pharmaceutical Co., Ltd.: key financial ratios 527
Table 353: Hanmi Holdings Co., Ltd.: key facts 529
Table 354: Hanmi Holdings Co., Ltd.: key financials ($) 530
Table 355: Hanmi Holdings Co., Ltd.: key financials (KRW) 530
Table 356: Hanmi Holdings Co., Ltd.: key financial ratios 530
Table 357: Dong-A Pharmaceutical Co., Ltd.: key facts 532
Table 358: Dong-A Pharmaceutical Co., Ltd.: key financials ($) 532
Table 359: Dong-A Pharmaceutical Co., Ltd.: key financials (KRW) 533
Table 360: Dong-A Pharmaceutical Co., Ltd.: key financial ratios 533
Table 361: Almirall S.A.: key facts 535
Table 362: Almirall S.A.: key financials ($) 535
Table 363: Almirall S.A.: key financials (€) 536
Table 364: Almirall S.A.: key financial ratios 536
SOURCE Reportlinker